DDInter948 DDInter1111
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension. It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] due to its lower risk of hepatotoxicity.
Macitentan {u} (Compound) binds {v} (Gene) EDNRA
Macitentan {u} (Compound) causes {v} (Side Effect) Infestation NOS
Macitentan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fedratinib
Macitentan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivacaftor
Macitentan {u} may lead to a major life threatening interaction when taken with {v} Clarithromycin
Macitentan {u} may lead to a major life threatening interaction when taken with {v} Apalutamide
Macitentan (Compound) binds EDNRA (Gene)
Macitentan (Compound) causes Infestation NOS (Side Effect)
Macitentan may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Macitentan may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Macitentan may lead to a major life threatening interaction when taken with Clarithromycin
Macitentan may lead to a major life threatening interaction when taken with Apalutamide